The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
Explore this paper's citation graph
Summary
The identification of ALK rearranged NSCLC, clinical characteristics of such patients, and clinical outcomes when treated with crizotinib are described.
- Type
- article
- Published
- 2015-03-22
- Cited by
- 3
- References
- 61
- OpenAlex
- https://openalex.org/W25801645
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:5433755
Keywords
Wavelet, Computer science, Image compression, Data compression, Computer vision
References
- A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer
- Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)
- Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer
- Heart rate decrease during crizotinib treatment and potential correlation to clinical response
- High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.
- Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
- Clinical Impact of Continued Crizotinib Administration after Isolated Central Nervous System Progression in Patients with Lung Cancer Positive for ALK Rearrangement
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
- Diagnosis of Lung Cancer in Small Biopsies and Cytology
- Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene addicted non-small cell lung cancer
- Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
- Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
- Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens.
Cited by
Related papers
- A Reconfigurable Computing Engine for Wavelet Transforms
- Reconfigurable Implementation of Wavelet Integer Lifting Transforms for Image Compression
- Implementation of Discrete Wavelet Transform Implementation of Discrete Wavelet Transform Implementation of Discrete Wavelet Transform Implementation of Discrete Wavelet Transform Processor For Image Compression Processor For Image Compression Processor For Image Compression Processor For Image Comp
- A partitioned wavelet-based approach for image compression using FPGA's
- FPGA implementation of wavelet packet transform with reconfigurable tree structure
- Parallel DSP implementation of wavelet transform in image compression
- Universal Wavelet Kernel Implementation Using Reconfigurable Hardware
- A Reconfigurable VLSI Structure for DWT
- A reconfigurable architecture for DWT and IDWT in JPEG2000
- An FPGA implementation of dynamic reconfigurable lifting-based wavelet packet processor for real-time scalable audio coding